We would love to hear your thoughts about our site and services, please take our survey here.
Note eagle -eyed TTB from twitter spotted AVA 31 new product in lab ?
https://twitter.com/tom_the_bomb__/status/1783534759273996629/photo/1
@Doggy100 Many thanks for sharing
Nicely fits with this article : Avacta chemists addressing the the right things .
https://www.aacr.org/blog/2024/01/31/experts-forecast-2024-part-4-cutting-edge-tech-for-oncology-drug-discovery/
-----------
"New therapeutics can be a driving force in extending patient survival and reducing deaths from cancer. Last year alone, the U.S. Food and Drug Administration (FDA) approved 17 new cancer drugs and expanded prior approvals for several others.
Despite this progress, drug discovery still has a long way to go, said Paul Workman, PhD, a professor and drug discovery expert at The Institute of Cancer Research in London.
“Ninety-five percent of cancer drugs tested in clinical trials never get approved,” he said. “This is because they end up being too toxic, ineffective, or no better than existing therapies once they are evaluated in patients, despite promising preclinical data.”
Paul Workman
Paul Workman, PhD
Moreover, only 14% of cancer patients in the United States are treated with precision medicine, and only 7% benefit—a sobering reality that Workman attributes in large part to the limited number of cancer drivers that are currently druggable. “The main reason for the low application of precision medicine is that most cancers are driven by genetic alterations for which we currently have no drugs.
“So, number one, we need to increase the clinical success rate of the drugs we are developing, and number two, we need to find ways to discover drugs against the so-called ‘undruggable’ targets,” he said. “In addition, we need to use intelligent combinations of new and old drugs to overcome drug resistance.”
Before new small-molecule drugs can reach the clinic, they must be designed to selectively block the function of the desired target protein and undergo extensive testing in the lab. This relies on researchers being able to identify new targets and engineer compounds against them that are safe and effective.
“This is where new technologies will help us,” Workman said. In 2024, he predicts that rapid advances in artificial intelligence (AI), chemical technology, and small-molecule chemical probes or tools will provide the cutting-edge resources needed to expand and accelerate drug discovery for cancer. "
"On 25 April, World Malaria Day 2024 will be marked under the theme “Accelerating the fight against malaria for a more equitable world”
Scroll / Check out all the LD Malaria Solutions products
https://www.launchdiagnostics.com/product/malaria-solutions/
The immediate priority is to commercialise the pre|CISIONTM platform.
For those that have the where·withal & foresight to see it through should eventually be a win/win for everyone involved .
The goals of the company need updating but some still valid (albeit execution so far somewhat open to question -fair enough )
---------------
"Our mission is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Clear communication of our corporate objectives and keeping our shareholders up to date with progress, as well as informing potential new investors about the investment opportunity, is at the core of our communications programme. I hope you find the information you are looking for and welcome any feedback
ALASTAIR SMITH, CHIEF EXECUTIVE OFFICER"
The immediate priority is to commercialise the pre|CISIONTM platform.
For those that have the where·withal & foresight to see it through should eventually be a win/win for everyone involved .
The goals of the company need updating but some still valid (albeit execution so far somewhat open to question -fair enough )
---------------
"Our mission is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Clear communication of our corporate objectives and keeping our shareholders up to date with progress, as well as informing potential new investors about the investment opportunity, is at the core of our communications programme. I hope you find the information you are looking for and welcome any feedback
ALASTAIR SMITH, CHIEF EXECUTIVE OFFICER"
"KEY TAKEAWAYS
The phase 1 trial aimed to investigate the efficacy and safety of AVA6000 in patients with FAP-positive solid tumors, focusing on targeted delivery and therapeutic outcomes.
Researchers noticed significant antitumor activity in FAP-positive tumors due to high doxorubicin concentrations in the TME, which supports AVA6000 efficacy."
FYI : Courtesy of twitter ;
PhysiciansWeekly
https://oncweekly.com/ava6000-targeted-doxorubicin-delivery-for-antitumor-activity/
FYI
"Launch Diagnostics France SASLaunch Diagnostics France SAS
220 followers220 followers
15h • 15h •
Follow
Le 25 avril est la journée mondiale de lutte contre le paludisme
Plus de 240 millions de cas de paludisme sont recensés chaque année, cette maladie mortelle a tué plus de 600 000 personnes en 2022 dans 60 pays différents.
Le déploiement du premier vaccin contre le paludisme approuvé par l'OMS est un réel espoir dans cette lutte.
En France, on compte environ 5500 cas d’importation chaque année. Dans son dernier point épidémiologique, Santé Publique France indique que 22 cas de paludisme importés ont été signalés à La Réunion, seulement au cours du premier trimestre 2024.
La Journée Mondiale de Lutte contre le Paludisme est donc une opportunité de renouveler notre engagement dans le diagnostic de cette maladie.
hashtag#malaria hashtag#paludisme hashtag#biologiemoléculaire hashtag#POC
…see more
Rate this translation
April 25 is World Malaria Day
More than 240 million cases of malaria are recorded each year, this deadly disease killed more than 600,000 people in 2022 in 60 different countries.
The rollout of the first malaria vaccine approved by the WHO is a real hope in this fight.
In France, there are about 5500 cases of importation each year. In its latest epidemiological update, Santé Publique France indicates that 22 cases of imported malaria have been reported in Reunion Island alone, only during the first quarter of 2024.
World Malaria Day is therefore an opportunity to renew our commitment to the diagnosis of this disease.
hashtag#malaria hashtag#paludisme hashtag#biologiemoléculaire hashtag#POC"
LD & Coris both attending conference . 𝗘𝗖𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 is approaching fast
Manufactuers offer a wide range of products that LD distibute
e.g , https://www.launchdiagnostics.com/products/
--------
Topfeed updates
Feed post number 1
View Launch Diagnostics Limited
Launch Diagnostics Limited likes this
Anatolia Geneworks
Anatolia GeneworksAnatolia Geneworks
5,047 followers5,047 followers
5d • 5d •
Follow
World Liver Day celebrated on the 19th of April, plays a vital role in raising awareness of chronic liver diseases.
The liver is one of the most vital organs in the human body which performs more than 500 complex functions.
Unfortunately, there are many chronic liver-related disease and 2 million people lose their lives each year from them. 1.5 billion people suffer from chronic liver diseases and 90% of the cases are preventable. One of the chronic liver diseases is viral hepatitis which comprises Hepatitis B (caused by Hepatitis B virus (HBV)) and Hepatitis C (caused by Hepatitis C virus (HCV)). Anatolia Geneworks’ Bosphore Hepatitis kits provide in vitro diagnostic tools for detection, screening, quantification, and genotyping against HBV and HCV.
On World Liver Day, as Anatolia Geneworks we want to encourage everyone to take good care of their liver and show our support to fight against chronic liver diseases with our diagnostic tools.
#worldliverday #liver
…see more
Rate this translation
World Liver Day celebrated on the 19th of April, plays a vital role in raising awareness of chronic liver diseases.
The liver is one of the most vital organs in the human body, which performs more than 500 complex functions."
Good Morning --- Foresight or Hindsight ?
Yesterday little top up taking AVCT monies invested to £60k . (current value is -61.38% down . On reflection might have been better just keeping that £60k locked away under the bed , but probably would have squandered it away on other items /stocks over last 4 years , anyway find researching a nice hobby /interest and learnt a lot and would have missed all this message board positivity that abounds ) ---.So not all lost - )
Still exists opportunity to recoup ..
Be interesting to see what happens next - Avacta Asset value / IP science POC already proven . Going forward would prefer to stick with Avacta management & will vote that way . The company accept that full commercialisation of IP potential will require at some stage - : external party involvement in some shape or form , so not that bothered about who/how/ when gets involved -- Future Execution & Delivery is paramount .
Previously stated Mid 2026 as my end target date , hopefully be back in paper profit long before then .
Good luck everyone .
Note LD manufacturer introducing new product @
https://www.vircell.com/media/filer_public/0a/8d/0a8d0b58-1768-45b0-aa51-1e18f5d794cb/vircell_eccmid24_-_innovation_and_pipeline_theater_invitation.pdf
Those baying for blood need to wait a bit longer .
LAST AGM "The Annual General Meeting will be held on Wednesday, 28 June 2023 at 10.30 a.m. BST at The Royal Society of Medicine, 1 Wimpole Street, Westminster, London W1G 0AE (the "Venue").
Nice stock to hold : Nationwide just started early days yet -
"#RNS Trading update for the year ending March 31 2024: Trading in line with market forecasts and management expectations.
Disclosing to the market we have now launched with 4 US Insurers in 4 US states:
Ohio,
New York,
New Jersey
and Washington
Positive feedback and excellent results from US launches has underlined the potential for LeakBot in the USA with both new partners, and potential for multi state rollouts with existing partners"
Sorry Hurst10 --my version automatically translates .
Pertinent ADC bits :
"3. Finding partners who can share the future of ADC through open collaboration
3. ADC secures a unique position as the food of the future
ADC stands for Antibody Drug Conjugate, which translates to 'antibody-drug conjugate'. It is characterized by attaching an antibody that recognizes the antigen protein of a specific cancer cell to the drug, and it attacks only the target cancer cells by connecting the antibody drug and the cytotoxic drug with a *linker. It has the advantage of increasing the therapeutic effect and minimizing side effects, so it is in the spotlight as a next-generation anticancer drug.
Along with the expansion of the ADC market, there is also a growing movement to secure pipelines. Daewoong Pharmaceuticals is also considering domestic and foreign ADC companies that will grow together through cooperation.
It is no exaggeration to say that Daewoong Pharmaceutical's R&D competitiveness began with various new drug collaborations. In order to continue the reputation of Korea's first bio drug, botulinum toxin, gastroesophageal reflux disease treatment, type 2 diabetes drug, and pulmonary fibrosis drug, the company is considering cooperation with companies that have new ADC drugs and conjugates.
In particular, Daewoong Pharmaceutical's New Drug Center, which is implementing smart and rapid R&D 'smart collaboration', is building various evaluation platforms for the development of treatments for anti-cancer, autoimmune, fibrosis, and metabolic diseases. First, based on the experience and master plan throughout the entire cycle from non-clinical to product approval, we actively share quality control, documentation, and CMC capabilities for R&D and manufacturing processes with partners. In addition, it also seeks to co-exist with startups by supporting a network of clinical KOLs (Key Opinion Leaders). As such, Daewoong Pharmaceutical's New Drug Center is always looking forward to meeting partners who will rewrite the future of ADC with an open mind.
*CMC: Chemistry, Manufacturing, and Control, which refers to the process development and quality control areas of making pharmaceuticals.
So far, we have looked at the trends in the pharmaceutical and bio industries announced at JPM 2024, and we have looked at Daewoong Pharmaceutical's focus on AI drug development, GLP-1 obesity treatment, and aromatic-drug conjugates (ADCs). Daewoong Pharmaceutical, which has solidified its position as a trend-leading pharmaceutical company, will continue its journey to become a global big pharma."
Good Morning
Note Daewoong ADC comments . ( Not related to existing Avacta JV stem cells @AffyXell Therapeutics Co.,Ltd. )
However might be a future opportunity for co·operation , anyway like the way Daewoong communicate .
"JPM 2024 was an opportunity to confirm that the biotech and pharmaceutical industries are still keenly interested in ADCs. In fact, in 2023, major pharmaceutical companies have made large investments to preempt the ADC market. This is a clear example of how many companies are choosing ADC as the food of the future.
The future of ADC is bright. This is evidenced by the projection that ADCs will account for more than 8% of the $375 billion global cancer market by $375 billion by 2028. The global ADC market is also expected to grow from $9.78 billion in 2023 to $19.8 billion by 2028, growing at a CAGR of 15.2%."
https://newsroom.daewoong.co.kr/archives/category/news
https://newsroom.daewoong.co.kr/archives/23405
Good Morning Weather very nice in Portugal - Diagnostics getting on with the day job - Therapeutics still in preparation for take- off : SP watchers looking for pennies - shareholders just sit back & relax .
------------------
Note : Coris/LD working together
Launch Diagnostics France SASLaunch Diagnostics France SAS
216 followers216 followers
2d • 2d •
Follow
Launch Diagnostics France SAS : Distributeur exclusif des produits de la gamme RESIST de Coris Bioconcept en France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
Rate this translation
Launch Diagnostics France SAS: Exclusive distributor of Coris Bioconcept's RESIST range products in France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
-----------
LD man in Germany getting to know the team
"Lena KastlLena Kastl
• 3rd+• 3rd+
Managing Director bei Launch Diagnostics Deutschland GmbHManaging Director bei Launch Diagnostics Deutschland GmbH
4d • 4d •
Follow
Get in touch and meet newly established Launch Diagnostics Deutschland GmbH at ECCMID in Barcelona!
https://www.linkedin.com/in/davidswilson/recent-activity/all/
Not a very cheery board today . I prefer to concentrate on the positives . .
Avacta managenent great foresight to obtain control of the science technology & hold the IP licences . As has been ably demonstrated recently in presentations the science works . Will eventually deliver substantial investment returns . Then the same folks bad mouthing the managenent today will then be singing their praises and we will all be very happy .
"Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April."
"A company’s IP strategy should manage and protect its intellectual property in a way that aligns with its overall business goals and strategy, ensuring that the intellectual property is being effectively protected, optimized (for value), and monetized (when possible), maximizing the value of the protected assets and their potential commercial benefits.
https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Note :
"CORIS BIOCONCEPTCORIS BIOCONCEPT
2,555 followers2,555 followers
3d • 3d •
Follow
𝗘𝗖𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 is approaching fast! 🚀
The congress will be held this year in the wonderful city of Barcelona 🇪🇸 from April 27th to 30th. We can't wait to be there!
Come and meet us at booth F-10 to discuss rapid tests and AntiMicrobial Resistance. 🦠🧫
https://www.eccmid.org/#
Visit our website for more information: https://www.corisbio.com
Fight #AMR together
#ECCMID2024 #Innovation #RapidTests #GlobalHealth #RaiseAwareness"